Chemical Genetic Interaction Profiling Reveals Determinants of Intrinsic Antibiotic Resistance in Mycobacterium tuberculosis

ABSTRACT Chemotherapy for tuberculosis (TB) is lengthy and could benefit from synergistic adjuvant therapeutics that enhance current and novel drug regimens. To identify genetic determinants of intrinsic antibiotic susceptibility in Mycobacterium tuberculosis, we applied a chemical genetic interaction (CGI) profiling approach. We screened a saturated transposon mutant library and identified mutants that exhibit altered fitness in the presence of partially inhibitory concentrations of rifampin, ethambutol, isoniazid, vancomycin, and meropenem, antibiotics with diverse mechanisms of action. This screen identified the M. tuberculosis cell envelope to be a major determinant of antibiotic susceptibility but did not yield mutants whose increase in susceptibility was due to transposon insertions in genes encoding efflux pumps. Intrinsic antibiotic resistance determinants affecting resistance to multiple antibiotics included the peptidoglycan-arabinogalactan ligase Lcp1, the mycolic acid synthase MmaA4, the protein translocase SecA2, the mannosyltransferase PimE, the cell envelope-associated protease CaeA/Hip1, and FecB, a putative iron dicitrate-binding protein. Characterization of a deletion mutant confirmed FecB to be involved in the intrinsic resistance to every antibiotic analyzed. In contrast to its predicted function, FecB was dispensable for growth in low-iron medium and instead functioned as a critical mediator of envelope integrity.

[1]  Thomas R. Ioerger,et al.  A Hidden Markov Model for identifying essential and growth-defect regions in bacterial genomes from transposon insertion sequencing data , 2013, BMC Bioinformatics.

[2]  T. Weisbrod,et al.  NADH Dehydrogenase Defects Confer Isoniazid Resistance and Conditional Lethality in Mycobacterium smegmatis , 1998, Journal of bacteriology.

[3]  R. Baker,et al.  Identifying essential genes in Mycobacterium tuberculosis by global phenotypic profiling. , 2015, Methods in molecular biology.

[4]  V. Dartois The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells , 2014, Nature Reviews Microbiology.

[5]  Giovanni Sotgiu,et al.  Efficacy and safety of meropenem–clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB , 2012, European Respiratory Journal.

[6]  J. Betts,et al.  Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling , 2002, Molecular microbiology.

[7]  C. Thompson,et al.  Role of the Mycobacterium tuberculosis P55 Efflux Pump in Intrinsic Drug Resistance, Oxidative Stress Responses, and Growth , 2009, Antimicrobial Agents and Chemotherapy.

[8]  Thomas R. Ioerger,et al.  Global Assessment of Genomic Regions Required for Growth in Mycobacterium tuberculosis , 2012, PLoS pathogens.

[9]  G. Lamichhane,et al.  Carbapenems and Rifampin Exhibit Synergy against Mycobacterium tuberculosis and Mycobacterium abscessus , 2015, Antimicrobial Agents and Chemotherapy.

[10]  W. Bishai,et al.  Characterization of a Novel Cell Wall-anchored Protein with Carboxylesterase Activity Required for Virulence in Mycobacterium tuberculosis* , 2007, Journal of Biological Chemistry.

[11]  D. T. Loots,et al.  Altered fatty acid metabolism due to rifampicin-resistance conferring mutations in the rpoB Gene of Mycobacterium tuberculosis: mapping the potential of pharmaco-metabolomics for global health and personalized medicine. , 2012, Omics : a journal of integrative biology.

[12]  Q. Gao,et al.  Assembling of the Mycobacterium tuberculosis Cell Wall Core* , 2016, The Journal of Biological Chemistry.

[13]  H. David,et al.  Intrinsic resistance of Mycobacterium tuberculosis to clarithromycin is effectively reversed by subinhibitory concentrations of cell wall inhibitors. , 2000, The Journal of antimicrobial chemotherapy.

[14]  J. Mckinney,et al.  Mycobacterium tuberculosis Resists Stress by Regulating PE19 Expression , 2015, Infection and Immunity.

[15]  R. Baker,et al.  The Oxidative Stress Network of Mycobacterium tuberculosis Reveals Coordination between Radical Detoxification Systems. , 2015, Cell host & microbe.

[16]  Thomas R. Ioerger,et al.  High-Resolution Phenotypic Profiling Defines Genes Essential for Mycobacterial Growth and Cholesterol Catabolism , 2011, PLoS pathogens.

[17]  N. Clumeck,et al.  Clinical use of the meropenem-clavulanate combination for extensively drug-resistant tuberculosis. , 2012, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[18]  L. Piddock,et al.  Accumulation of rifampicin by Mycobacterium aurum, Mycobacterium smegmatis and Mycobacterium tuberculosis. , 2000, The Journal of antimicrobial chemotherapy.

[19]  C. Nathan,et al.  TB drug development: immunology at the table , 2015, Immunological reviews.

[20]  J. Palomino,et al.  Efflux as a mechanism for drug resistance in Mycobacterium tuberculosis. , 2011, FEMS immunology and medical microbiology.

[21]  M. Waldor,et al.  A Transposon Screen Identifies Genetic Determinants of Vibrio cholerae Resistance to High-Molecular-Weight Antibiotics , 2016, Antimicrobial Agents and Chemotherapy.

[22]  Alison K. Hottes,et al.  Genetic Architecture of Intrinsic Antibiotic Susceptibility , 2009, PloS one.

[23]  K. Pethe,et al.  Nutrient-starved, non-replicating Mycobacterium tuberculosis requires respiration, ATP synthase and isocitrate lyase for maintenance of ATP homeostasis and viability. , 2010, Microbiology.

[24]  M. Glickman,et al.  Regulation of Mycobacterium tuberculosis cell envelope composition and virulence by intramembrane proteolysis , 2005, Nature.

[25]  L. Glimcher,et al.  Mycobacterium tuberculosis Rv2224c modulates innate immune responses , 2008, Proceedings of the National Academy of Sciences.

[26]  H. Nikaido,et al.  Mycobacterial cell wall: structure and role in natural resistance to antibiotics. , 1994, FEMS microbiology letters.

[27]  T. Dick,et al.  Reduced Drug Uptake in Phenotypically Resistant Nutrient-Starved Nonreplicating Mycobacterium tuberculosis , 2013, Antimicrobial Agents and Chemotherapy.

[28]  A. Kubler,et al.  Synthetic Lethality Reveals Mechanisms of Mycobacterium tuberculosis Resistance to β-Lactams , 2014, mBio.

[29]  Thomas R. Ioerger,et al.  Tryptophan Biosynthesis Protects Mycobacteria from CD4 T-Cell-Mediated Killing , 2013, Cell.

[30]  S. Smerdon,et al.  An attenuated mutant of the Rv1747 ATP-binding cassette transporter of Mycobacterium tuberculosis and a mutant of its cognate kinase, PknF, show increased expression of the efflux pump-related iniBAC operon , 2013, FEMS microbiology letters.

[31]  Thomas R. Ioerger,et al.  Comprehensive Essentiality Analysis of the Mycobacterium tuberculosis Genome via Saturating Transposon Mutagenesis , 2017, mBio.

[32]  C. Vilchèze,et al.  Altered NADH/NAD+ Ratio Mediates Coresistance to Isoniazid and Ethionamide in Mycobacteria , 2005, Antimicrobial Agents and Chemotherapy.

[33]  E. Fischer,et al.  Meropenem inhibits D,D‐carboxypeptidase activity in Mycobacterium tuberculosis , 2012, Molecular microbiology.

[34]  Liem Nguyen,et al.  Protein Kinase G Is Required for Intrinsic Antibiotic Resistance in Mycobacteria , 2009, Antimicrobial Agents and Chemotherapy.

[35]  V. Braun,et al.  Nucleotide sequences of the fecBCDE genes and locations of the proteins suggest a periplasmic-binding-protein-dependent transport mechanism for iron(III) dicitrate in Escherichia coli , 1989, Journal of bacteriology.

[36]  C. Gee,et al.  A Phosphorylated Pseudokinase Complex Controls Cell Wall Synthesis in Mycobacteria , 2012, Science Signaling.

[37]  Mithila Rajagopal,et al.  Multidrug Intrinsic Resistance Factors in Staphylococcus aureus Identified by Profiling Fitness within High-Diversity Transposon Libraries , 2016, mBio.

[38]  A. Camilli,et al.  Tn-seq; high-throughput parallel sequencing for fitness and genetic interaction studies in microorganisms , 2009, Nature Methods.

[39]  J. Sacchettini,et al.  Peptidoglycan synthesis in Mycobacterium tuberculosis is organized into networks with varying drug susceptibility , 2015, Proceedings of the National Academy of Sciences.

[40]  Liem Nguyen,et al.  Protein Kinase G from Pathogenic Mycobacteria Promotes Survival Within Macrophages , 2004, Science.

[41]  P. V. van Helden,et al.  Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux. , 2011, American journal of respiratory and critical care medicine.

[42]  J. Sacchettini,et al.  Mycobacterial Metabolic Syndrome: LprG and Rv1410 Regulate Triacylglyceride Levels, Growth Rate and Virulence in Mycobacterium tuberculosis , 2016, PLoS pathogens.

[43]  B. Aldridge,et al.  The Spectrum of Drug Susceptibility in Mycobacteria. , 2014, Microbiology spectrum.

[44]  P. Arjun,et al.  Guidelines For The Treatment Of Tuberculosis , 2001 .

[45]  G. Besra,et al.  Lcp1 Is a Phosphotransferase Responsible for Ligating Arabinogalactan to Peptidoglycan in Mycobacterium tuberculosis , 2016, mBio.

[46]  L. Via,et al.  Meropenem-Clavulanic Acid Shows Activity against Mycobacterium tuberculosis In Vivo , 2012, Antimicrobial Agents and Chemotherapy.

[47]  M. Glickman,et al.  Site-2 protease substrate specificity and coupling in trans by a PDZ-substrate adapter protein , 2013, Proceedings of the National Academy of Sciences.

[48]  C. Vilchèze,et al.  Precise Null Deletion Mutations of the Mycothiol Synthesis Genes Reveal Their Role in Isoniazid and Ethionamide Resistance in Mycobacterium smegmatis , 2011, Antimicrobial Agents and Chemotherapy.

[49]  M. Viveiros,et al.  Measuring efflux and permeability in mycobacteria. , 2015, Methods in molecular biology.

[50]  J. Blanchard,et al.  Meropenem-Clavulanate Is Effective Against Extensively Drug-Resistant Mycobacterium tuberculosis , 2009, Science.

[51]  S Miyano,et al.  Open source clustering software. , 2004, Bioinformatics.

[52]  Adamandia Kapopoulou,et al.  TubercuList--10 years after. , 2011, Tuberculosis.

[53]  Docking of the Periplasmic FecB Binding Protein to the FecCD Transmembrane Proteins in the Ferric Citrate Transport System of Escherichia coli , 2007, Journal of bacteriology.

[54]  Thomas R. Ioerger,et al.  TRANSIT - A Software Tool for Himar1 TnSeq Analysis , 2015, PLoS Comput. Biol..

[55]  H. Vogel,et al.  FecB, a periplasmic ferric-citrate transporter from E. coli, can bind different forms of ferric-citrate as well as a wide variety of metal-free and metal-loaded tricarboxylic acids. , 2016, Metallomics : integrated biometal science.

[56]  P. V. van Helden,et al.  Energy Metabolism and Drug Efflux in Mycobacterium tuberculosis , 2014, Antimicrobial Agents and Chemotherapy.

[57]  Alok J. Saldanha,et al.  Java Treeview - extensible visualization of microarray data , 2004, Bioinform..